October 27, 2025

‘Keep Sports Betting Fun’ — But Can It Be Safe?

Massachusetts tests new ways to curb gambling addiction amid growing calls for national regulation.

KFF Health News

October 27, 2025

How Hormones May Influence Tirzepatide Outcomes

Researchers show how reproductive stage and hormone therapy influence weight-loss outcomes in women treated with tirzepatide.

Conexiant

October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Tezepelumab FDA Approval Expands Use to Nasal Polyps

AstraZeneca and Amgen’s anti-thymic stromal lymphopoietin biologic reduces nasal polyp burden and corticosteroid use in the phase 3 WAYPOINT trial.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 16, 2025

‘Dying Alone’: The Growing Challenge for Seniors

An increasing number of older adults are living and dying alone, highlighting the need for physicians to address end-of-life care for patients without family or caregivers.

KFF Health News